New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome

Pharmacotherapy

Volumn 31, Issue 10, 2011, Pages 975-1016

  Davis, Estella M ^a   Packard, Kathleen A ^a   Knezevich, Jon T ^a   Campbell, Jennifer A ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

Author keywords

ACS; Acute coronary syndrome; AF; Anticoagulant; Antithrombotic; Atrial fibrillation

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; AZD 0837; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; DAREXABAN; EDOXABAN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LETAXABAN; LOW MOLECULAR WEIGHT HEPARIN; OTAMIXABAN; PLACEBO; RIVAROXABAN; TECARFARIN; THIENOPYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR EFFECT; CATHETER THROMBOSIS; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPISTAXIS; GASTRITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG EMBOLISM; NONHUMAN; OCCULT BLOOD; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SIDE EFFECT; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION; URINARY DYSFUNCTION; VENOUS THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG INTERACTIONS; HUMANS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 80053336306     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.10.975     Document Type: Review

References (127)

1. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:651-745. (Pubitemid 44472247)
2. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/ HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2011;123:104-23.
3. Camm AJ, Kirchhof P, Lip GYH, et al, for the European Heart Rhythm Association, European Association for Cardiothoracic Surgery. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
4. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2009;120:2271-306.
5. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1-157.
6. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation. Chest 2008;133:S546-92.
7. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 1994;154: 1449-57.
8. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994;154:1449-57.
9. Pham SV, Pham PC, Pham PM, Miller JM, Pham PT, Pham PA. Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Drug Des Devel Ther 2010;7:203-20.
10. The Medicines Company. Angiomax (bivalirudin) package insert. Parsippany, NJ; 2010.
11. Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008;29:155-65.
12. Samama MM, Gerotziafas GT. Newer anticoagulants in 2009. J Thromb Thrombolysis 2010;29:92-104.
13. Weitz JI, Hirsh J, Samama MM, for the American College of Chest Physicians. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines, 8th ed. Chest 2008;133(6 suppl):S234-56.
14. Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood 2001;97:2308-13. (Pubitemid 32291476)
15. Boehringer Ingelheim Pharmaceuticals, Inc. Pradaxa (dabigatran) package insert. Ridgefield, CT; 2011.
16. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase -clinical findings through hospital discharge. Circulation 1987;76:142-54. (Pubitemid 17093202)
17. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
18. Schulman S, Kearon C, for the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4.
19. Bayer Schering Pharma AG. Xarelto (rivaroxaban) European package insert. Berlin, Germany; 2008.
20. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009;48:1-22.
21. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011;31:326-43.
22. Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs vitamin K antagonists. Eur Heart J 2009;30:2897-907.
23. Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation 2009;120:1029-35.
24. Bavisotto LM, Ellis DJ, Milner PG, Combs DL, Irwin I, Canafax DM. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol 2010;50:743-53.
25. Ryn JV, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor - interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1-12.
26. Schirmer S, Baumhakel M, Neuberger HR, et al. Novel anticoagulants for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2010;56:2067-76.
27. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303. (Pubitemid 47283865)
28. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
29. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol 2010;70:703-12.
30. Galanis T, Thomson L, Palladino M, Merli GJ. New oral anticoagulants. J Thromb Thrombolysis 2011;31:310-20.
31. Haas S. Rivaroxaban: an oral, direct factor Xa inhibitor - lessons from a broad clinical study programme. Eur J Haematol 2009;82:339-49.
32. Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Aterioscler Vasc Biol 2010;30:376-81.
33. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75. (Pubitemid 351930851)
34. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86. (Pubitemid 351930852)
35. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-9.
36. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-80.
37. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363: 2499-510.
38. Cohen AT. Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients. Presented at the American College of Cardiology annual conference, New Orleans, LA, April 2-5, 2011.
39. Bayer. BAY59-7939 in atrial fibrillation once daily (OD). Updated 2008. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT00973245?term=NCT00973245&rank=1. Accessed May 5, 2011.
40. Bayer. BAY59-7939 Japanese in atrial fibrillation (2nd). Updated 2010. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT00973323?term=NCT00973323&rank=1. Accessed May 5, 2011.
41. Bayer. BAY59-7939, Japanese phase II in atrial fibrillation trial status. Updated 2008. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT00779064?term= NCT00779064&rank=1. Accessed May 5, 2011.
42. Bayer. Efficacy and safety of rivaroxaban for the prevention of stroke in subjects with non-valvular atrial fibrillation. Updated 2010. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT00494871?term=NCT00494871.&rank=1. Accessed May 5, 2011.
43. Patel MR, for ROCKET AF Executive Steering Committee. Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation [abstract]. American Heart Association Late-Breaking Clinical Trials II, November 15, 2010, abstract 21839.
44. Mahaffey KW, Fox KA, for the ROCKET AF Investigators. Rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for the prevention of stroke and embolism trial in atrial fibrillation: ROCKET AF, 2010. Available from http://www.cardio.se/fileArchive/Filer/AHA-2010- Chicago/ROCKET-A.pdf. Accessed January 31, 2011.
45. ROCKET AF Study Investigators. Rivaroxaban: once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159:340-7.e1.
46. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374:29-38.
47. Johnson & Johnson Pharmaceutical Research and Development, L.L.C. An efficacy and safety study for rivaroxaban in patients with acute coronary syndrome. Updated 2011. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT00809965?term= NCT00809965.&rank=1. Accessed May 5, 2011.
48. U.S. Food and Drug Administration. FDA news release: FDA approves Xarelto to reduce risk of blood clots after hip, knee replacements. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm261839.htm. Accessed July 27, 2011.
49. Johnson & Johnson. New drug application submitted to FDA for rivaroxaban for prevention of stroke in patients with atrial fibrillation, January 5, 2011. Available from http://www.jnj.com/connect/news/all/new-drug- application-submitted-to-fda-for-rivaroxaban-for-prevention-of-stroke-in- patients-with-atrial-fibrillation. Accessed May 5, 2011.
50. U.S. Food and Drug Administration. September 8, 2011: cardiovascular and renal drugs advisory committee meeting announcement. Available from http://www.fda.gov/AdvisoryCommittees/calendar/ucm261963.htm. Accessed July 27, 2011.
51. Roser-Jones C, Becker RC. Apixaban: an emerging oral factor Xa inhibitor. J Thromb Thrombolysis 2010;29:141-6.
52. Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010;38:448-58.
53. Umer Usman MH, Raza S, Raza S, Ezekowitz M. Advancement in antithrombotics for stroke prevention in atrial fibrillation. J Interv Card Electrophysiol 2008;22: 129-37.
54. Mehta RS. Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism. I. Factor Xa inhibitors. Expert Rev Hematol 2010;3:227-41.
55. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007;5:2368-75. (Pubitemid 350154345)
56. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375:807-15.
57. Buller H, Deitchman D, Prins M, Segers A, for the Botticelli Investigators and Writing Committee. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008;6:1313-18. (Pubitemid 352016310)
58. Lassen M, Gallus A, Pineo G, Raskob G. Randomized double-blind comparison of apixaban with enoxaparin for thromboprophylaxis after knee replacement: the ADVANCE-1 trial [abstract]. Blood 2008;112:abstract 31.
59. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363: 2487-98.
60. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
61. Bristol-Myers Squibb. Apixaban for the prevention of stroke in subjects with atrial fibrillation (ARISTOTLE). Updated 2011. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http:// clinicaltrials.gov/ct2/show/NCT00412984?term=NCT00412984&rank=1. Accessed May 5, 2011.
62. Alexander JH, Becker RC, Bhatt DL, et al, for the APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial. Circulation 2009;119:2877-85.
63. Alexander JH, Lopes RD, James S, et al, for the APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome [published online ahead of print July 24, 2011]. N Engl J Med. Available from http://dx.doi.org/10.1056/NEJMoa1105819.
64. Pfizer, Inc. A study to evaluate the safety of apixaban in acute coronary syndrome (ACS) Japanese patients. Updated 2011. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/ show/NCT00852397?term=NCT00852397.&rank=1. Accessed May 5, 2011.
65. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other thromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159:331-9.
66. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50:743-53.
67. Mendell J, Tachibana M, Shi M, Kunitada S. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol 2010;51:687-94.
68. Chung N, Jeon HK, Lien LM, et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost 2010;105:535-44.
69. Ridout G, de la Motte S, Niemczyk S, et al. Effect of renal function on edoxaban pharmacokinetics (PK) and on population PK/PK-PD model [abstract]. J Clin Pharmacol 2009;49:abstract 1124.
70. Fuji T, Wang CJ, Fujita S, Tachibana S, Kawai Y. Edoxaban in patients undergoing total hip arthroplasty: a phase IIb dose-finding study [abstract]. Blood 2008;112:abstract 2098.
71. Fuji T. Edoxaban versus enoxaparin for thromboprophylaxis after total knee replacement: the STARS E-3 trial. Presented at the 21st international congress of thrombosis, Milan, Italy, July 6-9, 2010.
72. Fuji T, Fujita S, Tachibana S. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial. Presented at the annual meeting of the American Society of Hematology, Orlando, FL, December 4-7, 2010.
73. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010;104:633-41.
74. Daiichi Sankyo, Inc. Global study to assess the safety and effectiveness of DU-176b vs standard practice of dosing with warfarin in patients with atrial fibrillation (EngageAFTIMI48). Updated 2010. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/ NCT00781391?term=NCT00781391&rank=1. Accessed May 5, 2011.
75. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635-41.
76. Turpie AG, Bauer KA, Davidson BL, et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009;101:68-76.
77. Ezekowitz MD, Connolly SJ, Diaz R, Hohnloser SH, Dorian P. A phase 2, randomized, parallel group, dose finding, multicenter, multinational study of the safety, tolerability and pilot efficacy of three blinded doses of the oral factor Xa inhibitor betrixaban compared with open-label dose-adjusted warfarin in patients with non-valvular atrial fibrillation (EXPLORE-Xa). Presented at the American College of Cardiology annual scientific sessions, Atlanta, GA, March 14-16, 2010.
78. Weitz JI. New oral anticoagulants in development. Thromb Haemost 2010;103:62-70.
79. Stringer F, Scott G, Kupfer S, et al. The pharmacokinetics and pharmacodynamics of TAK-442, an oral, direct factor Xa inhibitor following multiple dosing in healthy male subjects [abstract]. In: British Pharmacological Society Winter Conference Proceedings 2009:abstract CP026.
80. Stringer F, Scott G, Kupfer S, Cao C, Kawamura M. Absence of pharmacodynamic or pharmacokinetic interactions when TAK-442, an oral, direct factor Xa inhibitor, is co-administered with aspirin or clopidogrel [abstract]. Blood 2009;114:4175.
81. Konishi N, Hiroe K, Kawamura M. Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats. Thromb Res 2010;126:124-9.
82. Konishi N, Hiroe K, Kawamura M. Effects of fondaparinux and a direct factor Xa inhibitor TAK-442 on platelet-associated prothrombinase in the balloon-injured artery of rats. J Cardiovasc Pharmacol 2011;57:201-6.
83. Weitz JI, Cao C, Eriksson BI, et al. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost 2010;104:1150-7.
84. Takeda Global Research and Development Center, Inc. Safety and efficacy of TAK-442 in subjects with acute coronary syndromes. Updated 2010. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT00677053?term=NCT00677053.&rank=1. Accessed May 5, 2011.
85. Takeda Pharmaceutical Co. Takeda announces top line results from phase 2 study of investigational compound, TAK-441, for patients with ACS. Press release, October 26, 2010. Available from http://www.takeda.com/press/article- 38715.html. Accessed April 30, 2011.
86. Eriksson BI, Turpie AG, Lassen MR, et al. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty: a dose-finding study (ONYX-2). J Thromb Haemost 2010;8:714-21.
87. Eriksson BI, Turpie AG, Lassen MR, et al. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007;5:1660-5. (Pubitemid 47091408)
88. Astellas Pharma, Inc. A study evaulating safety and tolerability of YM150 compared to warfarin in subjects with atrial fibrillation (OPAL-2). Updated 2011. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT00938730?term=NCT00938730&rank=1. Accessed May 5, 2011.
89. Astellas Pharma, Inc. Direct factor Xa inhibitor YM150 for prevention of stroke in subjects with non-valvular atrial fibrillation. Updated 2009. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT00448214?term=NCT00448214.&rank=1. Accessed May 5, 2011.
90. Astellas Pharma, Inc. Study evaluating safety, tolerability, and efficacy of YM150 in subjects with acute coronary syndromes (RUBY-1). Updated 2010. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT00994292?term=NCT00994292&rank=1. Accessed May 5, 2011.
91. Paccaly A, Frick A, Rohatagi S, et al. Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure. J Clin Pharmacol 2006;46:37-44. (Pubitemid 43021712)
92. Sabatine MS, Antman EM, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009;374:787-95.
93. Hinder M, Frick A, Jordaan P, et al. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. Clin Pharmacol Ther 2006;80:691-702. (Pubitemid 44920219)
94. Cohen M, Bhatt DL, Alexander JH, et al. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 2007;115:2642-51.
95. sanofi-aventis. Effect of otamixaban versus unfractionated heparin + eptifibatide in patients with unstable angina/non ST elevation myocardial infarction undergoing early invasive strategy (TAO). Updated 2011. ClinicalTrials.gov. Available from http://clinicaltrials.gov/ct2/show/ NCT01076764?term=NCT01076764&rank=1. Accessed May 5, 2011.
96. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-16. (Pubitemid 44791162)
97. Stone GW, Bertrand M, Colombo A, et al. Acute catheterization and urgent intervention triage strategy (ACUITY) trial: study design and rationale. Am Heart J 2004;148:764-75.
98. Olsson SB, for the Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-8.
99. The electronic Medicines Compendium (eMC). Pradaxa 110 mg hard capsules: summary of product characteristics. Available from http://www.medicines.org.uk/ guides/pradaxa/Blood%20clotting/pradaxa%20110mg%20capsules. Accessed May 1, 2011.
100. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non-valvular atrial fibrillation (PETRO study). Am J Cardiol 2007;100:1419-26. (Pubitemid 47576022)
101. Boehringer Ingelheim Pharmaceuticals. A dose response study of dabigatran etexilate (BIBR 1048) in pharmacodynamics and safety in patients with non-valvular atrial fibrillation in comparison to warfarin. Updated 2011. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT01136408?term=NCT01136408.&rank=1. Accessed May 5, 2011.
102. Boehringer Ingelheim Pharmaceuticals. Long-term, open-label follow-up treatment of patients with A-fib who have been previously treated with BIBR 1048. Updated 2011. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT00157248?term= NCT00157248&rank=1. Accessed May 5, 2011
103. Boehringer Ingelheim Pharmaceuticals. RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed RE-LY trial. Updated 2011. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/ NCT00808067?term=NCT00808067&rank=1. Accessed May 5, 2011
104. Oldgren J, Budaj A, Granger C, et al. Randomized dabigatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel (RE-DEEM) [abstract]. Circulation 2009;120: 2160-1.
105. Boehringer Ingelheim Pharmaceuticals. Randomized, open label study of dabigatran etexilate in elective percutaneous coronary intervention. Updated 2011. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT00818753?term=NCT00818753&rank=1. Accessed May 5, 2011.
106. Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009;157:805-10, 810.e1-2.
107. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY Trial [letter]. New Engl J Med 2010;363:1875-87.
108. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-83.
109. Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010;9:1157-63.
110. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11.
111. Thompson Micromedex. Red book online. Dabigatran etexilate mesylate. Available from http://www-thomsonhc-com.cuhsl.creighton.edu/micromedex2/ librarian. Accessed May 2, 2011.
112. Beasley BN, Unger EF, Temple R. Anticoagulant options: why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 2011;364:1788-90.
113. U.S. Food and Drug Administration. Pradaxa capsules: special storage and handling requirements. Available from http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm249005.htm. Accessed April 15, 2011.
114. U.S. Food and Drug Administration. Boehringer Ingelheim advisory committee briefing document: dabigatran etexilate. August 27, 2010. Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ ucm226009.pdf. Accessed May 25, 2011.
115. Deinum J, Mattsson C, Inghardt T, Elg M. Biochemical and pharmacological effects of the direct thrombin inhibitor ARH067637. Thromb Haemost 2009;101:1051-9.
116. AstraZeneca. Long-term safety in atrial fibrillation patients. Updated 2009. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT00645853?term=NCT00645853&rank=1. Accessed May 5, 2011.
117. AstraZeneca. Atrial fibrillation (AF) patients not taking vitamin-K antagonist (VKA). Updated 2009. Clinical Trials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/ NCT00623779?term=NCT00623779.&rank=1. Accessed May 5, 2011.
118. ARYx Therapeutics. Comparison of ATI-5923, a novel vitamin K antagonist, with warfarin in patients requiring chronic anticoagulation (EmbraceAC). Updated 2009. Available from http://investors.aryx.com/releasedetail.cfm?ReleaseID= 394780. Accessed May 5, 2011.
119. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008;1:84-91.
120. Merck and Portola Pharmaceuticals. Phase 2 study showed investigational factor Xa inhibitor, betrixaban, reduced incidence of bleeding compared to warfarin in patients with atrial fibrillation. Press release March 15, 2010. Available from http://www.portola.com/pdfs/Betrixaban-EXPLORE-ACC-032010.pdf. Accessed May 8, 2011.
121. University Hospital, Grenoble. Study in healthy volunteers of the reversion by haemostatic drugs of the anticoagulant effect of new anti-thrombotics (REVNEWANTICO). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/ NCT01210755?term=NCT01210755&rank=1. Accessed May 8, 2011.
122. Hacke W, Patel MR, Becker RC, et al. Baseline characteristics of the ROCKET AF study: comparison with recent atrial fibrillation studies. Presented at the 19th European stroke conference, Barcelona, Spain, May 25-28, 2010.
123. Pisters R, Knottnerus I, Crijns HJ, et al. Antithrombotic guideline adherence in atrial fibrillation patients admitted with stroke. Do we use our safety-belt? European Society of Cardiology congress 2007 conference proceedings [abstract]. Eur Heart J 2007;28(suppl):131.
124. Marcucci M, Iorio A, Nobili A, et al. Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med 2010;21:516-23.
125. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2010;123:e240.
126. McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009;27:829-46.
127. Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thromb Haemost 2010;104:760-70.